Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice
Conclusions223RaCl2 has demonstrated “proof of concept” for use of TAT in cancer in clinical practice. The efficacy and safety of223RaCl2 monotherapy have been demonstrated in mCRPC, and223RaCl2 combination therapies are under investigation in various tumours. TAT has broad applicability across tumour types.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Nuclear Medicine | Prostate Cancer | Renal Cell Carcinoma | Study | Toxicology